Efficacy, Safety of an Investigational Dose of Semaglutide Injection in Adults With Type 2 Diabetes

by DailyBriefers
1 comment

Michael Radin, MD, executive director, Diabetes Cardio Renal Medical Director Team, Medical Affairs, Novo Nordisk, discusses the findings around the efficacy and safety of the 2 mg dose of semaglutide for the treatment of type 2 diabetes.

Pharmacy Times interviewed Michael Radin, MD, executive director, Diabetes Cardio Renal Medical Director Team, Medical Affairs, Novo Nordisk, on results from the SUSTAIN FORTE phase 3 clinical trial evaluating an investigational 2 mg dose of semaglutide (Ozempic; Novo Nordisk) injection in adults with type 2 diabetes.

During the discussion, Radin addresses the findings around the efficacy and safety of the 2 mg dose of semaglutide among this patient population.

You may also like

1 comment

psilocybin mushrooms buy online September 19, 2023 - 1:34 pm

577673 928284I recognize there is surely an excellent deal of spam on this weblog. Do you want aid cleansing them up? I may assist in between classes! 216453

Reply

Leave a Comment